A researcher in a lab looking at a tablet.

Category: Research

  • ,

    Dr. Ou at ALKtALK

    Dr. Ignatius Sai-Hong Ou – Professor in Hematology-Oncology, Medical Oncology University of California, Irvine Editor-in-Chief of Lung Cancer: Targets and Therapy Associate Editor of Journal of Thoracic Oncology Question: We

    Read More

  • ,

    International Ambassadors Survey- ALK Life Study

    An informal survey was conducted with our ALK International Ambassadors, volunteers from various countries who are passionate about sharing their experiences with others. A total of 22 countries were represented

    Read More

  • Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

    Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

    Read More

  • Gilteritinib overcomes Lorlatinib resistance in ALK-rearranged cancer

    by Mizuta et al. (Japan) A common problem we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known

    Read More

  • So what about immunotherapy?

    The hot phrase in cancer treatment is immunotherapy right now. What does it mean for ALK+patients?  Sometimes, you hear that immunotherapy does not work? But why are we trying to

    Read More

  • ,

    Dr. Vincent Lam at ALKtALK

    Director, Esophageal Cancer Research Program, Assistant Professor of Oncology Expertise: Esophageal Cancer & Lung cancer  Dr Lam: I am so excited to join your conversation tonight on a Sunday evening. 

    Read More

  • ,

    Dr. Benjamin Levy & NPC Rasheda Persinger join ALKtALK

    BENJAMIN PHILLIP LEVY, MD, Clinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor of Oncology RASHEDA PERSINGER, Nurse Practitioner Johns Hopkins Sidney

    Read More

  • The cover to Translational Lung Cancer Research.

    ALK Genetics 101

    About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to…

    Read More

  • Real World Data in Medical Research

    What is real world data vs. on-paper data?  Scientists create experiments in laboratories and present the best data they can in published papers for everyone to share.  That’s paper data. 

    Read More

  • ,

    Dr. Justin Gainor & Dr. Aaron Hata join ALKtALK

    Dr. Justin Gainor, MD Director of Center for Thoracic Cancers & Director of Targeted Immunotherapy at Massachusetts General Hospital, Boston Assistant Professor of Medicine at Harvard Medical School “It’s great

    Read More

  • ,

    Dr. Mark Awad & Dr. Roberto Chiarle join ALKtALK

    Mark Awad, MD, PhD  Clinical Director, Thoracic Oncology Treatment Center Assistant Professor of Medicine, Harvard Medical School I hope everyone is safe, warm, and healthy tonight. I am the Clinical

    Read More

  • Ensartinib: the unknown TKI

    Ensartinib (x396) is a medicine made by Xcovery, a biotech company based in Florida. It works closely with another company called Betta Pharmaceuticals in China for many of its trials.

    Read More